Clinical Research Directory
Browse clinical research sites, groups, and studies.
Targeting Vascular INflammation in Patients with Community-Acquired Pneumonia
Sponsor: Ottawa Heart Institute Research Corporation
Summary
The goal of this clinical trial is to learn if icosapent ethyl (Vascepa) works to lessen the amount of inflammation in adults diagnosed with Community-Acquired Pneumonia (CAP). The main question it aims to answer is: What is the effect of taking Vascepa on inflammation in the arteries in patients with CAP? Researchers will compare the drug Vascepa to a placebo (a look-alike submstance that contains no drug) to see if Vascepa works to reduce inflammation in patients with CAP. Participants wil: * take Vacscepa or a placebo twice a day for 6 months * Visit the clinic 3 times (baseline, 30 days, and 6 months) for checkups and tests
Official title: Targeting Vascular INflammation in Patients with Community-Acquired Pneumonia (TIN_CAP): a Multi-centre, Prospective, Randomized Control Trial
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
168
Start Date
2024-12-15
Completion Date
2027-06
Last Updated
2024-12-05
Healthy Volunteers
No
Interventions
Icosapent Ethyl 1000 MG Oral Capsule [Vascepa]
Participants randomized to the treatment arm will receive Vascepa 1000mg twice a day for 6 months.
Placebo
Placebo twice daily
Locations (1)
University of Ottawa Heart Institute
Ottawa, Ontario, Canada